Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. Tirzepatide presents a promising therapeutic option for managing heart failure, with significant metabolic and cardiovascular benefits. These real-world findings reinforce its potential role as a transformative treatment in improving clinical outcomes and quality of life for patients with HF without diabetes.
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo.
This is the first trial testing the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity.
At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure (defined as worsening heart failure symptoms in addition to hospitalization or the intensification of diuretic medications) compared with the placebo group.
The study demonstrated a cardiovascular benefit for patients at risk for adverse cardiovascular events who had type 2 diabetes. Compared with sitagliptin, a diabetes drug that has shown neutral effects on cardiovascular outcomes, semaglutide reduced the risk of stroke and heart attack by 18 percent. Treatment with tirzepatide lowered the risk of stroke, heart attack, and death by 13 percent compared to dulaglutide, another GLP-1 receptor agonist.
Tirzepatide was associated with significantly lower risks of major adverse cardiovascular events, all-cause mortality, and all-cause hospitalizations than Semaglutide. Patients receiving tirzepatide also had lower risks of cardiovascular outcomes like myocardial infarction, heart failure and heart failure exacerbations.
Data show tirzepatide achieves sustained weight loss, blood pressure, lipids, liver fat and kidney function improvements with decreased development of T2DM.
In the present trial, weight reduction with tirzepatide was accompanied by greater improvements with respect to all measured cardiovascular and metabolic risk factors, including waist circumference, systolic and diastolic blood pressure, and fasting insulin, lipid, and aspartate aminotransferase levels, than placebo.
